APOGEE THERAPEUTICS
Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders. The company aims to advance novel therapies to address patients’ needs. Based in San Francisco, California, Apogee Therapeutics was founded in 2022.
APOGEE THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Medical Therapeutics
Founded:
2022-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.apogeetherapeutics.com
Total Employee:
101+
Status:
Active
Total Funding:
652 M USD
Technology used in webpage:
Google Maps Amazon IPv6 U.S. Server Location Google Maps API Amazon Virginia Region CloudFront GoDaddy SSL Akamai Hosted Equinix
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Nuvalent
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
Prime Medicine
Prime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
RTW Investments
RTW Investments investment in Series B - Apogee Therapeutics
Fidelity
Fidelity investment in Series B - Apogee Therapeutics
Deep Track Capital
Deep Track Capital investment in Series B - Apogee Therapeutics
Wellington Management
Wellington Management investment in Series B - Apogee Therapeutics
OrbiMed
OrbiMed investment in Series B - Apogee Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Apogee Therapeutics
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series B - Apogee Therapeutics
Fairmount Funds Management
Fairmount Funds Management investment in Series B - Apogee Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Apogee Therapeutics
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series A - Apogee Therapeutics
Key Employee Changes
Official Site Inspections
http://www.apogeetherapeutics.com Semrush global rank: 5.38 M Semrush visits lastest month: 1.4 K
- Host name: 147.75.40.150
- IP address: 147.75.40.150
- Location: Amsterdam Netherlands
- Latitude: 52.2832
- Longitude: 4.7521
- Timezone: Europe/Amsterdam
- Postal: 1119
More informations about "Apogee Therapeutics"
Apogee Therapeutics - Crunchbase Company Profile
Apogee Therapeutics experienced significant financial growth as evidenced by a US$74 million increase in insider investments. The company's IPO saw a 42% increase following the successful performance of its eczema drug.See details»
Apogee Therapeutics, Inc. | Investor Relations
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology …See details»
Release Details - Apogee Therapeutics, Inc.
Aug 7, 2023 “The initiation of this Phase 1 study of APG777 represents an important advancement for Apogee, now a clinical-stage organization, and for our discovery research …See details»
Apogee Therapeutics - LinkedIn
Apogee Therapeutics | 17,211 followers on LinkedIn. Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the …See details»
Contact IR - Apogee Therapeutics, Inc.
The Investor Relations website contains information about Apogee Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Release Details - Apogee Therapeutics, Inc.
To learn more visit www.apogeetherapeutics.com. About Paragon Therapeutics. Paragon Therapeutics, Inc. is a biotechnology company leveraging cutting-edge science and …See details»
Apogee Therapeutics | Best-in-Class Therapies for Immunological …
Previously, Ms. Cox spent 10 years at Mercer, a global HR consulting firm, advising clients on a range of organization and people matters, including organization design, talent strategy, …See details»
Apogee Therapeutics | Best-in-Class Therapies for Immunological …
Michael Henderson, M.D., joined Apogee in September 2022 and serves as Chief Executive Officer and Board member. He is a proven biotechnology industry leader with expertise in …See details»
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial …
Jul 18, 2023 SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing …See details»
Apogee Therapeutics Launches with $169 Million to Develop …
Dec 7, 2022 Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological …See details»
Apogee Therapeutics Announces First Participants Dosed in Phase …
Mar 25, 2024 Apogee Therapeutics, LLC. Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the …See details»
Release Details - investors.apogeetherapeutics.com
6 days ago For more information, please visit https://apogeetherapeutics.com. Forward Looking Statements Certain statements in this press release may constitute “forward-looking …See details»
Meet The People that Power Progress - Apogee Therapeutics
Our team is comprised of experienced clinical and commercial leaders, drug developers, physicians, and operators who never accept “good enough” and are highly motivated to build …See details»
Apogee Therapeutics Highlights Progress and Best-in-Class …
Dec 2, 2024 Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep …See details»
Apogee Therapeutics Announces First Participants Dosed in
Aug 19, 2024 Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025. Initiation of the first clinical trial of APG777 and APG990 combination …See details»
Apogee Therapeutics Provides Pipeline Progress and Reports …
Mar 5, 2024 Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher …See details»
Release Details - Apogee Therapeutics, Inc.
Mar 12, 2024 SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology …See details»
Apogee Therapeutics Reports Breakthrough Half-Life Data for Key …
Dec 2, 2024 [email protected]. Media Contact: Dan Budwick 1AB [email protected]. FAQ. What were the key findings from APG808's Phase 1 trial for APGE …See details»
Apogee Therapeutics Highlights Pipeline Progress and Reports …
May 13, 2024 For more information, please visit www.apogeetherapeutics.com. Forward Looking Statements Certain statements in this press release may constitute “forward-looking …See details»